Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Xyotax STELLAR trial update

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Cell Therapeutics' Xyotax (paclitaxel poliglumex) showed a statistically significant, 40% improvement in survival compared to vinorelbine for first-line treatment of poor performance status (PS2) non-small cell lung cancer in the firm's STELLAR 4 trial (n=32, p=0.012, hazard ratio 0.6), the firm says. On-study deaths also were significantly reduced compared to vinorelbine or gemcitabine. CTI previously reported that the 381-patient trial showed a non-significant increase in median survival compared to controls receiving either gemcitabine or vinorelbine (1Pharmaceutical Approvals Monthly May 2005, p. 4)...

You may also be interested in...



Xyotax Fails To Show Survival Benefit Again; CTI Continues To Tout Safety Profile

CTI’s repeated STELLAR trial failures to show Xyotax survival benefit for lung cancer could delay NDA submission. Detailed STELLAR 2 and 4 data showing equivalent survival with significant reductions in side effects compared to docetaxel or gemcitabine/vinorelbine will be presented in July

QUOTED. 27 January 2021. Scott Whitaker.

Trade group AdvaMed should be consulted on how to implement the Defense Production Act to boost testing and PPE production, CEO Scott Whitaker said in a letter to President Biden.

Korean Biopharma IPOs Start Strong With Prestige

Following a successful offering by Prestige BioPharma in January, investors will keep their focus on another upcoming major listing by the SK Group's specialist vaccines arm SK Bioscience, which is likely to set the tone for the South Korean biopharma IPO market this year.

Topics

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel